Emerging antidementia drugs: A preliminary ethical view

Journal of the American Geriatrics Society

Volumn 46, Issue 6, 1998, Pages 784-787

  Post, Stephen G ^a   Whitehouse, Peter J ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

DEMENTIA; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; MEDICAL DECISION MAKING; MEDICAL ETHICS; NURSING HOME; PRACTICE GUIDELINE; SHORT SURVEY; TREATMENT PLANNING;

ARICEPT; CASE STUDIES; CLINICAL APPROACH/SOURCE; FAMILY MEMBERS; JUSTICE; MENTAL HEALTH THERAPIES; PROFESSIONAL PATIENT RELATIONSHIP; RISKS AND BENEFITS;

AGED; ALZHEIMER DISEASE; BENEFICENCE; CHOLINESTERASE INHIBITORS; DEMENTIA; ETHICS, MEDICAL; FEMALE; HUMANS; INDANS; MALE; NOOTROPIC AGENTS; PATIENT CARE PLANNING; PIPERIDINES; PROFESSIONAL-FAMILY RELATIONS; QUALITY OF LIFE; RISK ASSESSMENT; WITHHOLDING TREATMENT;

EID: 0031744633     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb03819.x     Document Type: Review

References (11)

1. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
2. Sacks O. Awakenings. New York: HarperCollins, 1990, p 53.
3. Post SG Slowing the progression of dementia: Ethical issues. Alzheimer Dis Assoc Disord 1997; 11(suppl 5): 34-36.
4. Winblad B, Hill S, Beerman B et al. Issues in the economic evaluation of treatment for dementia. Alzheimer Dis Assoc Disord 1997; 11(suppl 3): 39-44.
5. Post SG The Moral Challenge of Alzheimer Disease. Baltimore: The Johns Hopkins University Press, 1995.
6. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1217-1222.
7. Kelly CA, Harvey RJ, Cayton H. Drug treatments for Alzheimer's disease raise clinical and ethical problems. BMJ 1997; 314: 693-694.
8. Alzheimer's Association. Ethical considerations. Issues in death and dying. Chicago: Alzheimer's Disease Sc Related Disorders Association, 1997.
9. Knopman D, Schneider L, Davis K et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology 1996; 47: 166-167.
10. Whitehouse PJ Pharmacoeconomics of dementia. Alzheimer Dis Assoc Disord 1997; 11(Suppl 5):S22-S33.
11. Whitehouse PJ, Rabins PV. Quality of life and dementia. Alzheimer Dis Assoc Disord 1992; 6: 135-137.